Topics:
Thoracic Malignancies • Medical Oncology
For patients with advanced NSCLC who have radiographic disease progression on their follow-up scan after starting a PD-1 inhibitor, what characteristics (either clinical or radiographic) do you use to determine whether to continue with therapy or switch to something else?
I ask this question recognizing there is no great data here, and that "pseudo-progression" is rare, but I am looking for any guidance with regard to how you approach this decision (it comes up a lot!)
Answer from: Medical Oncologist at Academic Institution
I agree with @Edward B. Garon - there are two situations in which I would consider continuing therapy for another 4 or 6 weeks, 1) if as he has noted, there is some inconsistency (ie some areas worse and some better) AND the patient is feeling well, 2) if there is modest radiographic progressio...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
True pseudoprogression is very rare in non-small cell lung cancer. There are instances in which the scan results are inconsistent (e.g. some areas improved and some worsened), and I think that in such cases, it is reasonable to individualize treatment decisions. If scans at or after 8 weeks are clea...